Dr Jérémie Calais speaks to ecancer at ASCO GU 2020 in San Francisco about prostate-specific membrane antigen (PSMA) PET/CT imaging.
He explains the various indications associated with this imaging tool and the assessment of high-risk patients.
He also states that the detection of pelvic nodal disease is not entirely accurate, as some cases may be missed - and how this needs to be considered in the management of metastatic patients.
Dr Calais also discusses the implementation of this type of advanced imaging, which is used worldwide. However, he states that currently, there is no approved PSMA-PET agent approved in the US.